Amarin Corp Plc (AMRN)

[HDGabor]

j-

What I found:

(i) Doc 374: "Kurabayashi was considered by the USPTO during the prosecution of the Asserted Patents. See PX 21 (’728 Patent) at 8."

(ii) Doc 262 (12/702,889 application): "The prior art is either silent or teaches that there is no statistically significant change in Apo-B levels when patients with TG levels less than 150 mg/dl or between 150-499 mg/dl are treated with either 96% pure ethyl-EPA or a mixture of ethyl-EPA and DHA, or when a mixture of ethyl-EPA and DHA was administered to patients with TG levels above 500 mg/dl"

The (i) says it was … the (ii) is interesting if it was … (suggest was not).

Best,
G